A randomized screening trial was started in Europe to show the effect of early detection and treatment of prostate cancer on mortality (European Study on Screening of Prostate Cancer). In one centre (Rotterdam), the screening protocol initially consisted of 3 screening tests for all men: prostate-sp
Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam Region)
✍ Scribed by Kranse, Ries; Beemsterboer, Petra; Rietbergen, John; Habbema, Dik; Hugosson, Jonas; Schr�der, Fritz H.
- Publisher
- John Wiley and Sons
- Year
- 1999
- Tongue
- English
- Weight
- 163 KB
- Volume
- 39
- Category
- Article
- ISSN
- 0270-4137
No coin nor oath required. For personal study only.
✦ Synopsis
In the European Randomized Study of Screening for Prostate Cancer (ER-SPC, Rotterdam region), men aged 55-74 years are screened for prostate cancer by prostatespecific antigen (PSA) sampling, digital rectal examination (DRE), and transrectal ultrasound investigation (TRUS). All men with a PSA Ն4 ng/ml and/or a suspicious DRE and/or a suspicious TRUS are biopsied. METHODS. Logistic regression analysis was applied to derive a predictive index that equals the chance to find prostate cancer in a biopsy given the outcomes of the screening tests. This model was used to assess the number of cancers that could have been detected if all men had been biopsied (extrapolation). Furthermore, the model was used to study the possibilities for improvement of the current screening protocol. RESULTS. PSA was the dominant predictor for prostate cancer in a biopsy, followed by prostate volume, DRE, and TRUS result. It is assessed that 69% (95% CI, 52-86%) of cancers that could be identified if all men were biopsied are currently detected. Application of the same methods to screening data obtained in Go ¨teborg (the Swedish ERSPC partner) yielded almost identical results. It was found that, in the Rotterdam protocol, a considerable number of men were biopsied according to the screening protocol with an assessed lower chance to have prostate cancer than men who were not biopsied according to the protocol. CONCLUSIONS. The chance to detect prostate cancer in a biopsy can be modeled quite accurately as a function of serum PSA, prostate volume, DRE, and TRUS results. Important improvements in the screening protocol can be achieved by the application of the predictive index.
📜 SIMILAR VOLUMES
## Background: A consensus meeting on screening and global strategy for prostate carcinoma, held in antwerp in 1994, determined the willingness among european cancer prevention centers to pursue vigorously the collaborative formation of a multinational randomized screening trial. this trial was to